about
Role of biologics in severe eosinophilic asthma - focus on reslizumabObstructive sleep apnea and asthmaPatient preferences in severe COPD and asthma: a comprehensive literature reviewAsthma is Different in WomenStrategies for molecular classification of asthma using bipartite network analysis of cytokine expressionImpact of Age and Sex on Outcomes and Hospital Cost of Acute Asthma in the United States, 2011-2012Asthma Is More Severe in Older Adults.Predicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines.Economic burden of asthma: a systematic reviewThe role of omalizumab in the treatment of severe allergic asthma.Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations.Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial.Direct health care costs associated with asthma in British ColumbiaBronchial thermoplasty: a novel technique in the treatment of severe asthma.Health-care cost reduction resulting from primary-care allergy testing in children in Italy.Difficult-to-control asthma management through the use of a specific protocolThe effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial.Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines.Difficult-to-treat asthma, is it really difficult?New therapies and management strategies in the treatment of asthma: patient-focused developments.Advances in allergy management.The impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations and limitations in daily activities: a population-based observational study.Genetics of allergic diseases.Randomised evaluation of the Italian medicines use review provided by community pharmacists using asthma as a model (RE I-MUR).Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving.The economic burden of adult asthma in Cyprus; a prevalence-based cost of illness study.Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy ModelThe Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and childrenThe Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children.Clinical assessment of asthma symptom control: review of current assessment instruments.A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthmaDiscovery of a highly potent glucocorticoid for asthma treatmentAn evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studiesDiminished lipoxin biosynthesis in severe asthma.Chemical mediators and the resolution of airway inflammationComorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis.Predictors of exacerbations of asthma and COPD during one year in primary care.Pharmacogenetics and the development of personalized approaches for combination therapy in asthma.
P2860
Q26738503-4D56EC2A-8B3B-41CA-AE99-D5AC5CCD09F7Q26997776-932D1DA3-757E-4B1F-9297-3179416300F3Q27004230-AB97C93A-DE43-459C-9017-49812A4163D0Q28388843-2F752855-3033-446F-A921-D9984AF9DF40Q28394447-AAE5D8FD-59C8-4315-A7EA-7D54300AB4E8Q30276625-084D11FD-6BA9-4EF2-B8D4-DF3B61D91947Q30278970-F715BC72-8045-4FAA-A642-1AD79BDCFBEBQ30433497-3CDF6E9B-0F1B-4D59-9CA7-F0B800A28DFCQ33447966-374A0386-5474-457B-BE87-7E79E365FE46Q33591890-92A552BC-4F54-4E27-9519-00EA30488344Q33725032-B68F0D6F-24E3-402F-A3E4-FF31DC49673AQ33786076-58516749-3265-41AB-9FFA-E8D2FD45A177Q33818701-2497CD2E-CDDE-4869-9B85-58F217412C78Q33836152-D877B51C-7C85-4B73-8A82-F3E11C29A8FAQ34113269-581791EF-4EF0-459E-AE1A-FEFFCD27C598Q34154406-15212954-7783-4D56-9E19-15D828A8CBD7Q34197997-01BA5570-1BAA-4DF6-92E2-38C1EF3FCE9BQ34480446-AB7615F2-B59A-4EF1-A525-7A0C5E02E1D0Q34483166-4B15BA4E-D328-4364-A684-7A7626AE8618Q34504707-A0A231E6-8E52-4F51-89AC-EC39B158D97EQ35025262-6B9CEC42-6C22-4359-923D-EC948BB4DCA5Q35030819-96AB1D98-6723-4FBB-92E4-022DCAAEDF39Q35128108-2F392962-F4FE-4940-AEF0-26E23E008DC3Q35556785-8D8EF390-D332-439D-9F7B-220E39D0EE0EQ35576342-FA26DAA6-864C-49C2-9EC6-CABF90B4359DQ35985374-CC0D42E8-FD54-4F38-93F5-576A3EA957B4Q36311225-48A10D0A-812C-45B0-9A2F-EDC80E85BEB2Q36332037-9C0D0013-DBF7-4D0A-AE50-B52158FE2636Q36422663-88359DFD-E532-428D-B4A7-95D511C50AC6Q36566081-FE99697C-63B1-4121-8D77-B999229C6A64Q36581106-63E3B632-8EA2-4D68-AFB9-952F2049BB8FQ36642971-268A41AB-AF30-480C-8255-921C13A229D7Q36769629-7E81BB58-2DEC-40E9-A346-885230DE65CBQ37150465-9B197339-A4EA-4AF5-83F8-3C637A1DEDACQ37199668-042AA3BE-C24B-4E6D-BF24-4F6FF5F762A1Q37282577-2550F20A-A6A8-4467-B1CF-A046D432FC5AQ37306353-74AC3FA2-48EE-4BC8-B68D-E3EFB538C6AFQ37308652-2DEDD3F6-912E-474C-9FF4-0AEF8D2C8E45Q37320091-A17BAD50-6CC5-4F8B-8D4B-7C17C83C1E5AQ37425660-55286B02-A1A0-4A98-A5A0-7CB84D5CD2D4
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Costs of asthma according to the degree of severity.
@en
Costs of asthma according to the degree of severity.
@nl
type
label
Costs of asthma according to the degree of severity.
@en
Costs of asthma according to the degree of severity.
@nl
prefLabel
Costs of asthma according to the degree of severity.
@en
Costs of asthma according to the degree of severity.
@nl
P2093
P1476
Costs of asthma according to the degree of severity.
@en
P2093
J Serra-Batlles
P304
P356
10.1183/09031936.98.12061322
P577
1998-12-01T00:00:00Z